q-PCR and immunohistochemical (IHC) staining analyses demonstrated that both LPXN and PD-L1 were upregulated in tumor samples from patients exhibiting a favorable treatment response compared to those with a poor response (Fig. 1S, T, U). This evidence concerns the gene LPXN and neoplasm.